InflaRx’s Izicopan Reduces Kidney Injury in Preclinical Studies

PUBT · 2d ago
InflaRx’s Izicopan Reduces Kidney Injury in Preclinical Studies
  • InflaRx presented preclinical results showing oral izicopan reduced kidney injury in hamster models at Kidney Week 2026 in Denver.
  • Treatment improved kidney function markers and tissue damage; reductions in kidney fibrosis were not statistically significant.
  • Structural modeling indicated potentially lower drug-interaction risk than avacopan, supporting izicopan’s development for complement-driven kidney diseases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610221200PRIMZONEFULLFEED9851392) on October 22, 2026, and is solely responsible for the information contained therein.